3rd Quarter - Report

MEHLMAN CONSULTING, INC. for BIOGEN IDEC INC.

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans Pacific Partnership (TPP) trade agreement.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

International tax issues, including repatriation, deferral, check the box, pharmaceutical tax and transfer pricing.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Health care reform implementation issues; follow on biologics. Prescription drug user fee reauthorization and FDA reform.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Health reform implementation issues. Independent Payment Advisory Board. Medicare Part D Rebate. Part B Reimbursement. Budget Control Act of 2011 (Became PL 112-25 on August 2, 2011)

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.